-- Prostate Cancer Clinical Trials Advancing; Early Clinical Observations Look Promising –
Business and Operational Highlights
“The clinical development of our proprietary drug pipeline is advancing,” said
Fiscal 2019 Second Quarter vs Fiscal 2018 Second Quarter Financial Results
Fiscal 2019 Year-to-Date vs Fiscal 2018 Year-to-Date Financial Results
“We have achieved strong operating results through the first two quarters of fiscal 2019,” said Dr. Steiner. “Positive financial growth continued into our second quarter, with sequential quarterly increases to net revenues from both our FC2 US prescription and public sector channels. Growth of our US FC2 prescription channel is particularly noteworthy as it appears to be less reliant on traditional intermittent ordering patterns present in our FC2 public sector channel.”
“Based on current cash on hand and expected cash from current sales forecasts, along with existing sources of capital, the Company does not anticipate the need for a new equity financing until at least fiscal 2021,” said Dr. Steiner.
The Company does not expect to update the guidance for the full year fiscal 2019 provided above before the release announcing results for the next fiscal quarter. The Company notes that the statements of future performance made in this release, including the guidance for the full fiscal year 2019, are based upon current expectations and are subject to factors that could cause actual results to differ materially from those suggested here, including those factors set forth in the “Safe Harbor” Statement below.
Conference Call Event Details
In addition, investors may access a replay of the conference call the same day beginning at approximately
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
FINANCIAL SCHEDULES FOLLOW
Press Release Kari Sharp